X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CIPLA NATCO PHARMA/
CIPLA
 
P/E (TTM) x 10.6 35.0 30.2% View Chart
P/BV x 2.8 3.2 89.3% View Chart
Dividend Yield % 1.6 0.5 294.5%  

Financials

 NATCO PHARMA   CIPLA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
CIPLA
Mar-18
NATCO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,080663 162.9%   
Low Rs671479 140.1%   
Sales per share (Unadj.) Rs592.1189.0 313.2%  
Earnings per share (Unadj.) Rs188.417.6 1,070.8%  
Cash flow per share (Unadj.) Rs206.334.0 606.4%  
Dividends per share (Unadj.) Rs8.253.00 275.0%  
Dividend yield (eoy) %0.90.5 179.3%  
Book value per share (Unadj.) Rs833.6176.7 471.7%  
Shares outstanding (eoy) m36.90805.12 4.6%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x1.53.0 49.0%   
Avg P/E ratio x4.632.5 14.3%  
P/CF ratio (eoy) x4.216.8 25.3%  
Price / Book Value ratio x1.13.2 32.5%  
Dividend payout %4.417.1 25.7%   
Avg Mkt Cap Rs m32,311459,724 7.0%   
No. of employees `0004.823.6 20.5%   
Total wages/salary Rs m3,25626,901 12.1%   
Avg. sales/employee Rs Th4,522.56,446.1 70.2%   
Avg. wages/employee Rs Th674.01,139.4 59.2%   
Avg. net profit/employee Rs Th1,439.0600.0 239.8%   
INCOME DATA
Net Sales Rs m21,848152,193 14.4%  
Other income Rs m4043,577 11.3%   
Total revenues Rs m22,252155,769 14.3%   
Gross profit Rs m9,28428,264 32.8%  
Depreciation Rs m66213,228 5.0%   
Interest Rs m1541,142 13.5%   
Profit before tax Rs m8,87217,470 50.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1,9202,501 76.8%   
Profit after tax Rs m6,95214,166 49.1%  
Gross profit margin %42.518.6 228.8%  
Effective tax rate %21.614.3 151.2%   
Net profit margin %31.89.3 341.9%  
BALANCE SHEET DATA
Current assets Rs m21,307108,141 19.7%   
Current liabilities Rs m5,92038,322 15.4%   
Net working cap to sales %70.445.9 153.5%  
Current ratio x3.62.8 127.5%  
Inventory Days Days7397 75.5%  
Debtors Days Days10774 143.1%  
Net fixed assets Rs m14,986109,411 13.7%   
Share capital Rs m3691,610 22.9%   
"Free" reserves Rs m30,353140,682 21.6%   
Net worth Rs m30,760142,292 21.6%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m37,151228,606 16.3%  
Interest coverage x58.616.3 359.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 88.3%   
Return on assets %19.16.7 285.6%  
Return on equity %22.610.0 227.0%  
Return on capital %29.310.0 294.8%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32251,691 20.0%   
Fx outflow Rs m2,97821,033 14.2%   
Net fx Rs m7,34330,658 24.0%   
CASH FLOW
From Operations Rs m4,63614,628 31.7%  
From Investments Rs m-11,155-8,540 130.6%  
From Financial Activity Rs m6,509-3,855 -168.9%  
Net Cashflow Rs m-182,431 -0.7%  

Share Holding

Indian Promoters % 52.0 16.0 325.3%  
Foreign collaborators % 1.5 20.8 7.1%  
Indian inst/Mut Fund % 7.8 12.2 64.3%  
FIIs % 16.6 23.7 70.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.0 26.2 99.2%  
Shareholders   25,395 161,166 15.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON   STERLING BIOTECH  TORRENT PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; DHFL Down Over 9%(12:30 pm)

Share markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the realty sector, capital goods sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


May 22, 2019 02:41 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS